PolyPid (PYPD) Competitors

PolyPid (NASDAQ:PYPD) and Neuronetics (NASDAQ:STIM) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their community ranking, valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment.

Does the media favor PYPD or STIM?

In the previous week, Neuronetics had 4 more articles in the media than PolyPid. MarketBeat recorded 9 mentions for Neuronetics and 5 mentions for PolyPid. PolyPid's average media sentiment score of 1.08 beat Neuronetics' score of -0.37 indicating that PolyPid is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PolyPid	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neuronetics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do analysts rate PYPD or STIM?

PolyPid currently has a consensus price target of $12.00, suggesting a potential upside of 243.84%. Neuronetics has a consensus price target of $4.67, suggesting a potential upside of 481.52%. Given Neuronetics' higher probable upside, analysts clearly believe Neuronetics is more favorable than PolyPid.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PolyPid	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Neuronetics	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Which has preferable earnings and valuation, PYPD or STIM?

PolyPid has higher earnings, but lower revenue than Neuronetics. Neuronetics is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PolyPid	N/A	N/A	-$23.86M	-$7.81	-0.45
Neuronetics	$71.35M	0.34	-$30.19M	-$1.23	-0.65

Is PYPD or STIM more profitable?

PolyPid has a net margin of 0.00% compared to Neuronetics' net margin of -50.09%. Neuronetics' return on equity of -141.24% beat PolyPid's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PolyPid	N/A	-1,219.71%	-134.48%
Neuronetics	-50.09%	-141.24%	-32.77%

Do insiders and institutionals believe in PYPD or STIM?

26.5% of PolyPid shares are owned by institutional investors. Comparatively, 53.6% of Neuronetics shares are owned by institutional investors. 24.7% of PolyPid shares are owned by insiders. Comparatively, 9.8% of Neuronetics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Does the MarketBeat Community prefer PYPD or STIM?

Neuronetics received 101 more outperform votes than PolyPid when rated by MarketBeat users. However, 77.14% of users gave PolyPid an outperform vote while only 68.45% of users gave Neuronetics an outperform vote.

Company	Underperform	Outperform
PolyPid	Outperform Votes 27 77.14%	Underperform Votes 8 22.86%
Neuronetics	Outperform Votes 128 68.45%	Underperform Votes 59 31.55%

Which has more risk and volatility, PYPD or STIM?

PolyPid has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500. Comparatively, Neuronetics has a beta of 2.21, indicating that its share price is 121% more volatile than the S&P 500.

Summary

Neuronetics beats PolyPid on 10 of the 17 factors compared between the two stocks.